^
    2d
    MAZINGA: Zanubritnib and Anti-MAG Neuropathy (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Azienda Ospedaliera di Padova
    New P2 trial
    |
    Brukinsa (zanubrutinib)
    2d
    Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 mutation • CD20 positive • TP53 wild-type
    |
    Imbruvica (ibrutinib)
    2d
    NCI-2018-00410: Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    2d
    A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (clinicaltrials.gov)
    P2, N=87, Completed, Eli Lilly and Company | Active, not recruiting --> Completed
    Trial completion
    |
    Jaypirca (pirtobrutinib)
    3d
    Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, Hackensack Meridian Health | Trial completion date: Oct 2025 --> Jul 2026
    Trial completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide
    3d
    Ibrutinib enhances stem-cell-memory T cell generation during early T cell activation but inhibits T cell proliferation. (PubMed, Cell Immunol)
    In contrast, ibrutinib added 48 h post-activation did not show these effects. These findings suggest that caution should be exercised when incorporating ibrutinib into ex vivo expansion system for adoptive non-genetically engineered T cells or combining ibrutinib with these T cell immunotherapies in clinical trial settings.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CCR7 (Chemokine (C-C motif) receptor 7) • FAS (Fas cell surface death receptor) • IL15 (Interleukin 15) • IL7 (Interleukin 7)
    |
    Imbruvica (ibrutinib)
    3d
    A 3D lymph node model for chronic lymphocytic leukaemia recapitulates microenvironmental features and drug response in vitro. (PubMed, Dis Model Mech)
    Venetoclax treatment revealed greater CLL protection within the LN environment than in BM, whereas ibrutinib's mobilizing effect was comparable. This 3D LN model offers an effective ex vivo platform for studying microenvironment-tumour interactions and tissue-specific drug responses.
    Preclinical • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    4d
    A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    5d
    Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) (clinicaltrials.gov)
    P3, N=132, Recruiting, Ono Pharmaceutical Co. Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • temozolomide • Velexbru (tirabrutinib)
    5d
    BRAWM: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, Sunnybrook Health Sciences Centre | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine
    5d
    REMODEL-2: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov)
    P3, N=1011, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rhapsido (remibrutinib)